• Imricor files amendment to Form 10 registration statement with SEC
• Amendment addresses minor edits and clarifications raised in SEC review process
• Form 10 expected to become effective on May 17, 2026

Imricor Medical Systems, Inc. (ASX: IMR) has announced that it has filed an amendment to its Form 10 Registration Statement (originally filed on March 18) with the U.S. Securities and Exchange Commission (SEC). The amendment addresses certain minor edits and clarifications raised in the SEC review process, which follows the standard process for the SEC review of such filings. The Company expects the Form 10 to become effective on May 17, 2026. The Form 10 is not being used to conduct a U.S. initial public offering or a U.S. stock exchange listing. Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures, including capital equipment and single-use devices. The Company's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand, and U.S. FDA approval is in process, with further approvals in other geographies such as Australia being planned.